• Home
  • About Us
    • About Us
    • Subscribe
    • Privacy Policy
  • Advertise
    • Advertise On IP Watch
    • Editorial Calendar
  • Videos
  • Links
  • Help

Intellectual Property Watch

Original news and analysis on international IP policy

  • Copyright
  • Patents
  • Trademarks
  • Opinions
  • People News
  • Venues
    • Bilateral/Regional Negotiations
    • ITU/ICANN
    • United Nations – other
    • WHO
    • WIPO
    • WTO/TRIPS
    • Africa
    • Asia/Pacific
    • Europe
    • Latin America/Caribbean
    • North America
  • Themes
    • Access to Knowledge/ Open Innovation & Science
    • Food Security/ Agriculture/ Genetic Resources
    • Finance
    • Health & IP
    • Human Rights
    • Internet Governance/ Digital Economy/ Cyberspace
    • Lobbying
    • Technical Cooperation/ Technology Transfer
  • Health Policy Watch

Medicines Patent Pool Responds To Critics Of Gilead Licence

08/11/2011 by Intellectual Property Watch 1 Comment

Share this:

  • Click to share on Twitter (Opens in new window)
  • Click to share on LinkedIn (Opens in new window)
  • Click to share on Facebook (Opens in new window)
  • Click to email this to a friend (Opens in new window)
  • Click to print (Opens in new window)

The Medicines Patent Pool, which aims to increase access to affordable, high-quality medicines for HIV/AIDS patients in low and middle income countries, has issued a response to concerns about its recent deal with a large pharmaceutical company.

The licence agreement with Gilead (IPW, Public Health, 12 July 2011) has drawn criticism from some non-governmental groups for not going far enough to open access to middle-income markets. The International Treatment Preparedness Coalition (ITPC) circulated a petition with more than 160 signatures opposing the Gilead-Pool agreement in its current form (IPW, Public Health, 11 October 2011).

The Pool said in its response that the Gilead deal is not a template for the future, and that it includes more countries in its scope than any other HIV licence to date. The response also details how the licence does not undermine flexibilities contained within the World Trade Organization Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS). It also seeks to address concerns related to production of generic products in India and elsewhere.

The Medicines Patent Pool works to increase access to AIDS medicines by “negotiating with patent holders to share their intellectual property with the Pool, and then licensing it to other producers to facilitate the production of affordable generic medicines well-adapted for use in resource-poor settings,” it says on the MPP website.

The Medicines Patent Pool response is here.

Share this:

  • Click to share on Twitter (Opens in new window)
  • Click to share on LinkedIn (Opens in new window)
  • Click to share on Facebook (Opens in new window)
  • Click to email this to a friend (Opens in new window)
  • Click to print (Opens in new window)

Related

Creative Commons License"Medicines Patent Pool Responds To Critics Of Gilead Licence" by Intellectual Property Watch is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Filed Under: IP-Watch Briefs, IP Policies, Themes, Venues, Development, English, Health & IP, Innovation/ R&D, Patents/Designs/Trade Secrets, WHO

Trackbacks

  1. Intérêt de l’entreprise et choix stratégiques : les licences concédées par Gilead au Medicines Patent Pool | Intellectual Property Watch says:
    15/03/2012 at 12:17 pm

    […] Article tiré du site Internet d’Intellectual Property Watch : http://www.ip-watch.org Lien vers l’article : http://www.ip-watch.org/2011/07/21/corporate-self-interest-and-strategic-choices-gilead-licenses-to-medicines-patent-pool/ Liens dans cet article : [1] M. Brook K. Baker : #bio [2] http://www.medicinespatentpool.org/LICENSING/Patent-Status-of-ARVs : http://www.medicinespatentpool.org/LICENSING/Patent-Status-of-ARVs [3] Medicines Patent Pool Signs Deal With Indian Generics Producer : http://www.ip-watch.org/2011/10/11/medicines-patent-pool-signs-deal-with-indian-generics-producer/ [4] Medicines Patent Pool Responds To Critics Of Gilead Licence : http://www.ip-watch.org/2011/11/08/medicines-patent-pool-responds-to-critics-of-gilead-licence/ [5] Medicines Patent Pool Boosts HIV Drug Prospects With First Licence : http://www.ip-watch.org/2011/07/12/medicines-patent-pool-boosts-hiv-drug-prospects-with-first-licence/ Related Articles:Medicines Patent Pool Responds To Critics Of Gilead Licence […]

    Reply

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.

  • Email
  • Facebook
  • LinkedIn
  • RSS
  • Twitter
  • Vimeo
My Tweets

IPW News Briefs

Saudis Seek Alternative Energy Partners Through WIPO Green Program

Chinese IP Officials Complete Study Of UK, European IP Law

Perspectives on the US

In US, No Remedies For Growing IP Infringements

US IP Law – Big Developments On The Horizon In 2019

More perspectives on the US...

Supported Series: Civil Society And TRIPS Flexibilities

Civil Society And TRIPS Flexibilities Series – Translations Now Available

The Myth Of IP Incentives For All Nations – Q&A With Carlos Correa

Read the TRIPS flexibilities series...

Paid Content

Interview With Peter Vanderheyden, CEO Of Article One Partners

More paid content...

IP Delegates in Geneva

  • IP Delegates in Geneva
  • Guide to Geneva-based Public Health and IP Organisations

All Story Categories

Other Languages

  • Français
  • Español
  • 中文
  • اللغة العربية

Archives

  • Archives
  • Monthly Reporter

Staff Access

  • Writers

Sign up for free news alerts

This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy

Copyright © 2022 · Global Policy Reporting

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.